Clinical Trial Update: 177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for 177Lu-PSMA-I&T radioligand therapy in metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-I&T (177Lu-PSMA-I&T)

Snippet

Sponsor: Nanjing First Hospital, Nanjing Medical University | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: UNKNOWN